Novoprotein Scientific

Novoprotein Scientific EBIT per Share

The EBIT per Share of Novoprotein Scientific (688137.SS) as of Oct 24, 2026 is -0.95 CNY. In the previous year, EBIT per Share was -0.79 CNY — a change of 20.37% (lower).

EBIT per Share

-0.95CNY

YoY

20.37%

Last updated:

EBIT per Share of Novoprotein Scientific is 2025 -0.95 CNY. EBIT per Share of Novoprotein Scientific was 2024 -0.79 CNY. It decreases by 20.37% lower compared to the previous year.

The Novoprotein Scientific EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-0.13 CNY
Jan 1, 2020
1.36 CNY
Jan 1, 2021
2.76 CNY
Jan 1, 2022
1.61 CNY
Jan 1, 2023
-0.08 CNY
Jan 1, 2024
-0.79 CNY
Jan 1, 2025
-0.95 CNY
The Novoprotein Scientific EBIT per Share history
YEAREBIT per ShareYoY
-0.95CNY+20.37%
-0.79CNY+840.30%
-0.08CNY-105.22%
1.61CNY-41.75%
2.76CNY+103.78%
1.36CNY-1,181.41%
-0.13CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Novoprotein Scientific Stock analysis

What does Novoprotein Scientific do? Novoprotein Scientific Inc generates revenue through the development, production, and sale of recombinant protein solutions. The company offers target and factor proteins, recombinant antibodies, enzymes, and reagents, along with technical services. Its main products include novel coronavirus diagnostic antibodies, antigens, pseudoviruses, non-structural proteins, and mRNA raw material enzymes and reagents. These products are primarily sold to customers in biological medicine, life science research, in vitro diagnostics, and mRNA vaccine drug sectors. The firm serves both domestic and international markets with its comprehensive portfolio of protein-based solutions. The company's revenue streams are derived from the sale of specialized biological reagents and technical services. Customers in the pharmaceutical and biotechnology industries purchase these products for research and diagnostic applications. The firm's focus on novel coronavirus-related products positions it within the healthcare and vaccine development markets. Novoprotein Scientific Inc targets both domestic Chinese and overseas markets for its protein application solutions. Novoprotein Scientific Inc's business model centers on providing high-value recombinant protein products and services for the life science and healthcare sectors. The company's product portfolio includes diagnostic tools for viral detection and mRNA vaccine components. These offerings are tailored to meet the needs of research institutions, diagnostic laboratories, and pharmaceutical companies. The firm's technical services support customers in developing and implementing protein-based solutions across multiple applications. Novoprotein Scientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novoprotein Scientific stock

EBIT per Share of Novoprotein Scientific is -0.95 CNY in 2025.

EBIT per Share of Novoprotein Scientific changed from -0.79 CNY to -0.95 CNY, representing a 20.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Novoprotein Scientific since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Novoprotein Scientific

All Key Metrics — Novoprotein Scientific